Bulletin
Investor Alert

Market Pulse Archives

July 16, 2020, 7:39 a.m. EDT

J&J to start Phase 1 trial for coronavirus vaccine candidate next week

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -2.55% were down 0.3% in premarket trading on Thursday after CFO Joseph Wolk told CNBC that the company expects the Phase 1 trial for its COVID-19 vaccine candidate to begin next week. J&J reported second-quarter earnings on Thursday. Wolk said the Phase 1 trial is expected to enroll more than 1,000 participants, primarily between the ages of 18 and 55 years old, although the company also plans to include a group of people who are 65 years old or older in the early-stage trial. He also said that J&J is in talks with the National Institutes of Health to move up the timeline for the anticipated Phase 3 trial to late September. "The science still has to play out," Wolk said. J&J's stock is up 1.6% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.63% is down 0.1%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 144.32
-3.78 -2.55%
Volume: 7.25M
Oct. 19, 2020 4:00p
P/E Ratio
22.68
Dividend Yield
2.80%
Market Cap
$389.92 billion
Rev. per Employee
$603,509
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,426.92
-56.89 -1.63%
Volume: 2.19B
Oct. 19, 2020 5:05p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.